Mainstream cholesterol theory strikes out again

Quoting Derek Lowe:

"Lilly’s evacetrapib did just you would want a CETP inhibitor, or any lipid-targeting cardiovascular drug, to do. It raised HDL by 130% compared to placebo, and lowered LDL by 35%. But the cardiovascular outcomes (MI, angina, stroke, and so on) were absolutely identical between the treatment group and the placebo group. At one point, if you’d asked cardiologists to predict the effects of a compound that affected cholesterol levels in this way, you’d have gotten some pretty enthusiastic guesses. But not now."

It's almost as if there's something else really causing cardiovascular disease.  Like, say, infection.

Haha, not before time! ...............................Sarah

Completed Stratton/Wheldon regime for aggressive secondary progressive MS in June 2007, after four years, three of which intermittent.   Still improving bit by bit and no relapses since finishing treatment.